# EDGAR Filing Document

**Accession Number:** 0001705843
**File Stem:** 0001193125-23-048730
**Filing Date:** 2023-2
**Character Count:** 15135
**Document Hash:** 069f3f0de981127d14df92a4160d9621
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-048730.hdr.sgml**: 20230224

**ACCESSION NUMBER**: 0001193125-23-048730

**CONFORMED SUBMISSION TYPE**: 425

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20230224

**DATE AS OF CHANGE**: 20230224

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Calyxt, Inc.
- **CENTRAL INDEX KEY:** 0001705843
- **STANDARD INDUSTRIAL CLASSIFICATION:** AGRICULTURE CHEMICALS [2870]
- **IRS NUMBER:** 271967997
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 425
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38161
- **FILM NUMBER:** 23666910

**BUSINESS ADDRESS:**
- **STREET 1:** 2800 MOUNT RIDGE ROAD
- **CITY:** ROSEVILLE
- **STATE:** MN
- **ZIP:** 55113
- **BUSINESS PHONE:** (651) 683-2807

**MAIL ADDRESS:**
- **STREET 1:** 2800 MOUNT RIDGE ROAD
- **CITY:** ROSEVILLE
- **STATE:** MN
- **ZIP:** 55113
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Calyxt, Inc.
- **CENTRAL INDEX KEY:** 0001705843
- **STANDARD INDUSTRIAL CLASSIFICATION:** AGRICULTURE CHEMICALS [2870]
- **IRS NUMBER:** 271967997
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 425

**BUSINESS ADDRESS:**
- **STREET 1:** 2800 MOUNT RIDGE ROAD
- **CITY:** ROSEVILLE
- **STATE:** MN
- **ZIP:** 55113
- **BUSINESS PHONE:** (651) 683-2807

**MAIL ADDRESS:**
- **STREET 1:** 2800 MOUNT RIDGE ROAD
- **CITY:** ROSEVILLE
- **STATE:** MN
- **ZIP:** 55113

Filed by Calyxt, Inc.

Pursuant to Rule 425 under the Securities Act of 1933

and deemed filed pursuant to Rule 14a-12

under the Securities Exchange Act of 1934

Subject Company: Calyxt, Inc.

Commission File No.: 001-38161

**On February 6, 2023, Cibus Global, LLC published the following post on LinkedIn and Facebook:** 

Farm Journal captures the emerging business of plant gene editing as transformative to farming and agriculture: <u>https://www.agweb.com/news/business/technology/gene-editing-merger-focuses-accelerates-trait-licensing</u>

**On February 6, 2023, Rory Riggs reposted Cibus Global, LLC's post on LinkedIn with the following post:** 

The Farm Journal totally understood the importance of the merger.

**On February 6, 2023, Cibus Global, LLC published the following post on Twitter:** 

@FarmJournal captures the emerging business of plant gene editing as transformative to farming and agriculture: <u>https://www.agweb.com/news/business/technology/gene-editing-merger-focuses-accelerates-trait-licensing</u>

**On February 6, 2023, Cibus Global, LLC posted the following article on the "News" tab of its website:**![LOGO](g338275tx001.jpg)

**TECHNOLOGY** 

**Gene Editing Merger Focuses, Accelerates Trait Licensing**![LOGO](g338275tx0022-1.jpg)

"Gene editing is the analog to digital moment for agriculture," says Rory Riggs, co-founder of Cibus and newly named CEO of the merged company

(Cibus)

---

| | |
|:---|:---|
| By **MARCY ECKELKAMP** January 24, 2023 | ![LOGO](g338275tx3.jpg) |

---

Cibus and Calyxt, which have been pioneering companies in the space of gene edited crops, will merge.

"Gene editing is the analog to digital moment for agriculture," says Rory Riggs, co-founder of Cibus and newly named CEO of the merged company. "Gene editing is timebound and efficient. We can accomplish things with better accuracy and speed that is going to change the scale of breeding opportunities in which farmers can expect big changes in what's possible in the next ten years."

Riggs says the merger and the first products the new company will bring to market have the opportunity to cement the idea of a "real business" behind gene editing.

"Because of the advances in gene editing technology, it's time for the industry to consider the 'Productivity Trait Business' as a natural competitor or counterpart to the 'Crop Protection Chemical Business,'" he says.

The Cibus vision is to build a platform for every major crop to deliver Productivity Traits that address the major productivity challenges such pests, diseases and fertilizer using with genetics as opposed to chemicals.

------

The new company will focus on the five dominant global crops: corn, wheat, soybeans, rice and canola; that are planted on 500 million acres in North America, South America and the EU. Cibus' Rapid Trait Development System (RTDS) will be the springboard in this product development.

"Our first traits are in canola and rice." he says. "The first canola product is for pod shatter reduction. Cibus has received germplasm from 10 seed company customers for its patented pod shatter trait. In 2023 it will begin transfer to our customers in North America with the expectation of commercial launch in 2025 of our first "Cibus Powered" traits. In addition, in 2023, we are preparing to transfer two different herbicide resistance traits in rice in the elite germplasm of a leading North American rice seed company for commercialization"

Riggs says another advantage to its RTDS technologies it does not integrate any Foreign DNA/Transgene which is the hallmark of GMO. All three of its initial products have been determined not to be regulated articles through USDA APHIS "Am I Regulated" (now the SECURE Process) for regulating gene edited products. This designation materially speeds up time to develop and commercialize new traits.

The complementary platform Calyxt has developed is helping Cibus grow its second pillar of products: sustainable low carbon ingredients. These projects are focused on renewable low-carbon ingredients that can replace fossil fuel-based ingredients and diesel fuel and lower greenhouse gas emissions.

Riggs says, "By the time this deal closes, we expect to have three major product announcements in the sustainability traits industry."

He adds that in addition to highlighting what's possible with gene editing, the combined business will also benefit from additional growth capacities now under one company umbrella. The new company's corporate headquarters will be in San Diego, California and the company will use the Calyxt offices, laboratory, and breeding facilities in Roseville, Minnesota.

"We will be establishing one of the world's most sophisticated facilities for trait development and next generation plant breeding," he says.

**<u>Cautionary Statement Regarding Forward-Looking Statements</u>**

The information included in this communication includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of present or historical fact included herein, regarding the transactions, the ability of the parties to the merger agreement to consummate the transactions, the benefits of the transactions, the combined company's future performance following the transactions, and the potential for global regulatory developments, as well as Calyxt's, Cibus' and the combined company's respective strategies, future operations, financial positions, prospects and plans as well as the objectives of management are forward-looking statements. Words such as "expects," "continues," "may," "will," "approximately," "intends," the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words.

These forward-looking statements are based on the current expectations and assumptions of Cibus' and Calyxt's management about future events and are based on currently available information as to the outcome and timing of future events. Forward-looking statements are subject to risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Calyxt and Cibus. These risks include, but are not limited to, (i) the risk that the conditions to the closing of the proposed transactions are not satisfied, including the failure to obtain stockholder approval of matters related to the proposed transactions in a timely manner or at all, (ii) uncertainties as to the timing of the consummation of the proposed transactions, (iii) risks related to Calyxt's capital resources and the ability of Calyxt and Cibus, respectively, to correctly estimate and manage their respective operating expenses and expenses associated with the proposed transactions, (iv) risks related to Calyxt's continued listing on the Nasdaq Capital Market until closing of the proposed transactions, (v) risks associated with the possible failure to realize certain anticipated benefits of the proposed transactions, including with respect to future financial and operating results; (vi) uncertainties regarding the impact that any delay in the closing would have on the anticipated cash resources of the combined company upon closing and other events and unanticipated spending and costs that could reduce the combined company's cash resources; (vii) the potential for the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement; (viii) the possible effect of the announcement, pendency or completion of the merger on Calyxt's or Cibus' business relationships, operating

------

results and business generally; (ix) risks related to unexpected costs related to the merger; (x) the potential for, and uncertainty associated with the outcome of, any legal proceedings that may be instituted against Calyxt or Cibus or any of their respective directors or officers related to the merger agreement or the transactions contemplated thereby; (xi) risks associated with the ability of Calyxt and Cibus to protect their respective intellectual property rights; (xii) the potential impact of competitive responses to the proposed transactions and changes in expected or existing competition; (xiii) the possibility that Calyxt, Cibus or the combined company may be adversely affected by other economic, business, or competitive factors; (xiv) risks associated with the loss of key employees of Calyxt or Cibus; (xv) risks associated with changes in applicable laws or regulations and the potential impact of such changes on Calyxt's, Cibus' or the combined company's ability to advance product development and commercialization; and (xvi) other risks and uncertainties identified from time to time in documents filed or to be filed with the SEC by Calyxt or the combined company, including those discussed in the "Risk Factors" section of Calyxt's Annual Report on Form 10-K, which was filed with the SEC on March 3, 2022, and Quarterly Reports on Form 10-Q, which were filed with the SEC on August 4, 2022 and November 3, 2022, respectively. Should one or more of the risks or uncertainties occur, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. In addition, the forward-looking statements included in this communication represent Calyxt's and Cibus' views as of the date hereof. Calyxt and Cibus anticipate that subsequent events and developments will cause the respective company's views to change. Calyxt and Cibus specifically disclaim any obligation to update such forward-looking statements in the future, except as required under applicable law. These forward-looking statements should not be relied upon as representing Calyxt's or Cibus' views as of any date subsequent to the date hereof.

**<u>Important Additional Information</u>**

In connection with the proposed transactions, Calyxt has filed materials with the Securities and Exchange Commission (the "SEC"), including a registration statement on Form S-4 (the "Form S-4"), which includes a proxy statement of Calyxt for the stockholders of Calyxt and that will serve as a prospectus of Calyxt and an information statement of Cibus, and other documents relating to the proposed transactions. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS, INCLUDING THE FORM S-4 AND THE PROXY STATEMENT/PROSPECTUS INCLUDED THEREIN BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT CALYXT, CIBUS AND THE PROPOSED TRANSACTIONS. After the Form S-4 is declared effective, the definitive proxy statement included in the Form S-4 will be mailed to Calyxt stockholders as of a record date to be established for voting on the matters to be considered at the Calyxt special meeting of stockholders being held in connection with the transactions. The Form S-4, the proxy statement/prospectus included therein, and other materials filed by Calyxt with the SEC may be obtained free of charge from the SEC's website (www.sec.gov) or from Calyxt by directing a request to: Calyxt, Inc., 2800 Mount Ridge Road, Roseville, MN 55113.

**<u>Participants in the Solicitation</u>**

Calyxt, Cibus and their respective directors, executive officers and other members of management may be deemed to be participants in the solicitation of proxies with respect to the proposed transactions under the rules of the SEC. Information about the directors and executive officers of Calyxt is set forth in Calyxt's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on March 3, 2022, and its definitive proxy statement for its 2022 Annual Meeting of Shareholders, which was filed with the SEC on April 19, 2022.

Other information regarding persons who may, under the rules of the SEC, be deemed to be participants in the proxy solicitation and a description of their interests in the transaction, by security holdings or otherwise, are included in the proxy statement/prospectus included in the Form S-4 and other relevant materials filed with the SEC regarding the proposed transaction. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from Calyxt or the SEC's website, as indicated above.

**<u>No Offer or Solicitation</u>**

This communication shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Calyxt, Cibus or the combined company, nor shall there be any sale of any such securities in any state or jurisdiction in

------

which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made in the United States except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, a public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone or internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.